Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Hackensack, NJ, US. The stock last traded at $2.58, up 6.19% on the session, giving a market capitalisation of $207.5M. On trailing twelve-month figures it carries a trailing P/E of 13.34, a net margin of 20.1%. Its beta of 0.01 implies it has historically moved less than the broad market.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Protalix BioTherapeutics, Inc. is most often compared with the following Healthcare names: